3 Things That Will Make or Break Novavax's Earnings Report Next Week
Investors -- and governments -- have rallied behind Novavax (NASDAQ: NVAX) since the start of the coronavirus vaccine race. The major excitement began after the company won a $1.6 billion order from the U.S. government last summer. At the time, it was one of the government's biggest investments in a vaccine developer. And the shares soared more than 2,700% last year.
Since, Novavax has lost a considerable amount of steam -- in spite of strong clinical trial data. The stock has gained 73% this year. But it's down nearly 40% from a high reached in February. Can Novavax's dynamism return? Next week's earnings report may offer some clues. Here are the three things that will make it or break it for the clinical stage biotech.
Image source: Getty Images.
Source Fool.com
